Development and Validation of a Sensitive LC-MS/MS Method for the Determination of N-Nitroso-Atenolol in Atenolol-Based Pharmaceuticals

The recent detection of N-nitroso-atenolol, a mutagenic and potentially carcinogenic impurity in atenolol-based pharmaceuticals, has raised serious safety concerns and emphasized the need for stringent analytical control. This study developed and validated a highly sensitive LC-MS/MS method for quan...

Full description

Saved in:
Bibliographic Details
Main Authors: Soonho Kwon, Sang-Hyun Ahn, Yongha Chang, Joon-Sang Park, Hwangeui Cho, Jung-Bok Kim
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Separations
Subjects:
Online Access:https://www.mdpi.com/2297-8739/12/5/122
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850256008040939520
author Soonho Kwon
Sang-Hyun Ahn
Yongha Chang
Joon-Sang Park
Hwangeui Cho
Jung-Bok Kim
author_facet Soonho Kwon
Sang-Hyun Ahn
Yongha Chang
Joon-Sang Park
Hwangeui Cho
Jung-Bok Kim
author_sort Soonho Kwon
collection DOAJ
description The recent detection of N-nitroso-atenolol, a mutagenic and potentially carcinogenic impurity in atenolol-based pharmaceuticals, has raised serious safety concerns and emphasized the need for stringent analytical control. This study developed and validated a highly sensitive LC-MS/MS method for quantifying N-nitroso-atenolol in both active pharmaceutical ingredients (APIs) and finished products. Quantification was carried out using multiple reaction monitoring (MRM) under positive-mode electrospray ionization (ESI). Separation was performed on a C18 reversed-phase column with a gradient of water and methanol containing 0.1% formic acid. The method was validated to meet a specification limit of 15 ng/mg, with a linear range of 0.5–80 ng/mL, effectively covering 10–400% of the regulatory threshold. The method exhibited an excellent performance in terms of specificity, accuracy, precision, linearity, and robustness. It achieved a limit of detection (LOD) of 0.2 ng/mL (0.30 ng/mg) and a limit of quantification (LOQ) of 0.5 ng/mL (0.75 ng/mg), alongside a comprehensive uncertainty analysis with an expanded uncertainty of ±3.86 mg/kg. Application to commercial atenolol products confirmed the reliability and practical utility of the method. This validated approach offers a critical tool for pharmaceutical manufacturers and regulatory agencies to monitor and control N-nitroso-atenolol, ensuring compliance and enhancing patient safety.
format Article
id doaj-art-1f221bb1128a40ef8ed9ef8fc1093ed7
institution OA Journals
issn 2297-8739
language English
publishDate 2025-05-01
publisher MDPI AG
record_format Article
series Separations
spelling doaj-art-1f221bb1128a40ef8ed9ef8fc1093ed72025-08-20T01:56:45ZengMDPI AGSeparations2297-87392025-05-0112512210.3390/separations12050122Development and Validation of a Sensitive LC-MS/MS Method for the Determination of N-Nitroso-Atenolol in Atenolol-Based PharmaceuticalsSoonho Kwon0Sang-Hyun Ahn1Yongha Chang2Joon-Sang Park3Hwangeui Cho4Jung-Bok Kim5Corporation VIVAGEN, Seongnam 13219, Republic of KoreaCorporation VIVAGEN, Seongnam 13219, Republic of KoreaCorporation VIVAGEN, Seongnam 13219, Republic of KoreaCorporation VIVAGEN, Seongnam 13219, Republic of KoreaInstitute of New Drug Development, School of Pharmacy, Jeonbuk National University, Jeonju 54896, Republic of KoreaDepartment of Yuhan Biotechnology, School of Bio-Health Sciences, Yuhan University, Bucheon 14780, Republic of KoreaThe recent detection of N-nitroso-atenolol, a mutagenic and potentially carcinogenic impurity in atenolol-based pharmaceuticals, has raised serious safety concerns and emphasized the need for stringent analytical control. This study developed and validated a highly sensitive LC-MS/MS method for quantifying N-nitroso-atenolol in both active pharmaceutical ingredients (APIs) and finished products. Quantification was carried out using multiple reaction monitoring (MRM) under positive-mode electrospray ionization (ESI). Separation was performed on a C18 reversed-phase column with a gradient of water and methanol containing 0.1% formic acid. The method was validated to meet a specification limit of 15 ng/mg, with a linear range of 0.5–80 ng/mL, effectively covering 10–400% of the regulatory threshold. The method exhibited an excellent performance in terms of specificity, accuracy, precision, linearity, and robustness. It achieved a limit of detection (LOD) of 0.2 ng/mL (0.30 ng/mg) and a limit of quantification (LOQ) of 0.5 ng/mL (0.75 ng/mg), alongside a comprehensive uncertainty analysis with an expanded uncertainty of ±3.86 mg/kg. Application to commercial atenolol products confirmed the reliability and practical utility of the method. This validated approach offers a critical tool for pharmaceutical manufacturers and regulatory agencies to monitor and control N-nitroso-atenolol, ensuring compliance and enhancing patient safety.https://www.mdpi.com/2297-8739/12/5/122N-nitroso-atenololNDSRIsLC-MS/MS
spellingShingle Soonho Kwon
Sang-Hyun Ahn
Yongha Chang
Joon-Sang Park
Hwangeui Cho
Jung-Bok Kim
Development and Validation of a Sensitive LC-MS/MS Method for the Determination of N-Nitroso-Atenolol in Atenolol-Based Pharmaceuticals
Separations
N-nitroso-atenolol
NDSRIs
LC-MS/MS
title Development and Validation of a Sensitive LC-MS/MS Method for the Determination of N-Nitroso-Atenolol in Atenolol-Based Pharmaceuticals
title_full Development and Validation of a Sensitive LC-MS/MS Method for the Determination of N-Nitroso-Atenolol in Atenolol-Based Pharmaceuticals
title_fullStr Development and Validation of a Sensitive LC-MS/MS Method for the Determination of N-Nitroso-Atenolol in Atenolol-Based Pharmaceuticals
title_full_unstemmed Development and Validation of a Sensitive LC-MS/MS Method for the Determination of N-Nitroso-Atenolol in Atenolol-Based Pharmaceuticals
title_short Development and Validation of a Sensitive LC-MS/MS Method for the Determination of N-Nitroso-Atenolol in Atenolol-Based Pharmaceuticals
title_sort development and validation of a sensitive lc ms ms method for the determination of n nitroso atenolol in atenolol based pharmaceuticals
topic N-nitroso-atenolol
NDSRIs
LC-MS/MS
url https://www.mdpi.com/2297-8739/12/5/122
work_keys_str_mv AT soonhokwon developmentandvalidationofasensitivelcmsmsmethodforthedeterminationofnnitrosoatenololinatenololbasedpharmaceuticals
AT sanghyunahn developmentandvalidationofasensitivelcmsmsmethodforthedeterminationofnnitrosoatenololinatenololbasedpharmaceuticals
AT yonghachang developmentandvalidationofasensitivelcmsmsmethodforthedeterminationofnnitrosoatenololinatenololbasedpharmaceuticals
AT joonsangpark developmentandvalidationofasensitivelcmsmsmethodforthedeterminationofnnitrosoatenololinatenololbasedpharmaceuticals
AT hwangeuicho developmentandvalidationofasensitivelcmsmsmethodforthedeterminationofnnitrosoatenololinatenololbasedpharmaceuticals
AT jungbokkim developmentandvalidationofasensitivelcmsmsmethodforthedeterminationofnnitrosoatenololinatenololbasedpharmaceuticals